Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,343.72
(
-0.39%
)
US TECH 100
22,240.00
(
-1.17%
)
Dow Jones
45,216.14
(
0.11%
)
Brent Oil
108.57
(
0.30%
)
Bitcoin
66,577.99
(
0.94%
)
News Focus
News Focus
Post# of 257313
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

biomaven0

Send PM Follow Ignore
Followers 82
Posts 4778
Boards Moderated 0
Alias Born 02/27/2007

biomaven0

Re: xavierprivas post# 207904

Wednesday, 01/11/2017 5:44:24 PM

Wednesday, January 11, 2017 5:44:24 PM

Post# of 257313
It was two patents denied review - 8,609,646 and 8,466,172

The hepcidin patent likely serves to block AKBA in US as well given any FDA label would talk about use for epo-resistant patients with high hepcidin.

Surviving this review bodes very well for chances of these patents surviving given lower standards of proof and broader claim construction here.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today